Improved Focus and More-Profitable Business Mix Narrate No-Moat ICU Medical's Turnaround Story

With roots as a supplier of infusion consumables, ICU Medical enhanced its product mix through the transformative acquisition of Hospira Infusion Systems from Pfizer in 2017 by bringing infusion pumps, a broader consumables offering, and intravenous solutions manufacturing into the fold. The firm has become a more complete provider with the acquisition of Smiths Medical (various IV-related pumps and other medical supplies) in 2022. In our view, ICU’s focus on building a more comprehensive portfolio adds to the long-term stability of its revenue mix thanks to lengthy contracts and a hallmark razor-and-blade model in its systems business. We think unrivaled scale in consumables may help it generate excess returns eventually, though its portfolio has lost differentiation. By expanding the product offering and incorporating pumps into the business mix, ICU Medical aims to enhance the value proposition that it can offer customers by bundling consumables with larger pump-related contracts.